U.S. government scientists have raised questions about the potential risks to patients of heart attacks and blood clots from Abbott Laboratories’ novel coronary stent that dissolves after it is implanted.
Abbott is seeking U.S. approval to sell the stent, called Absorb, as an alternative to metal stents currently used to prop open arteries cleared of blockages. Unlike traditional stents that remain in place after implantation, Absorb is designed to disappear within three years of the procedure.
